ACD Pharma

ACD Pharma is a Norwegian R&D company that is at the forefront in the development of bacteriophage products. The company is currently in the process of establishing a large-scale bacteriophage production facility.

Vacancies

Open Application

About us

WHO states that “antibiotic resistance is one of the biggest threats to global health, food security, and development today". ACD Pharma aims to help remedy the situation by developing bacteriophage products that may serve as an alternative or an important supplement to antibiotics.


ACD Pharma launched the world's first bacteriophage product for use against harmful bacteria in aquaculture back in 2018. Several similar products are currently in the pipeline or in active field trials. Additionally, ACD Pharma is involved in several bacteriophage projects in the field of human health.


ACD Pharma has research facilities at the Norwegian University of Life Sciences in Ås and are currently establishing a new R&D department at Lofoten Bio Centre in Lofoten, where the company is also headquartered. ACD Pharma is owned by Nordly Holding.